Novo Nordisk is applying for an expanded US label for its long-acting insulin Tresiba, hoping to gain an upper hand on Sanofi's older rival Lantus. Its data submitted to the FDA shows that ...

The results of the ONWARDS 2 trial of insulin icodec showed that it was as effective as daily dosing with Novo Nordisk's Tresiba (insulin degludec) once per day at controlling blood glucose ...

We recently published a list of 10 Best Diabetes Stocks To Buy According to Billionaires. In this article, we are going to ...

Novo Nordisk will lower the US list prices for Tresiba and Fiasp by more than 70% starting January 1, 2026, following the lowering of its other insulin products on January 1, 2024. The company ...

Its portfolio includes insulin analogs, GLP-1 receptor agonists, and oral antidiabetic drugs like Rybelsus, Ozempic, and Tresiba. Novo Nordisk A/S (NYSE:NVO) delivered exceptional financial ...

Dosage will vary depending on the individual. Tresiba (insulin degludec injection) was approved in 2015. It is a long-acting injectable insulin that is used to improve glycemic control in adults ...

Now, a study has found that, in mice, aspartame triggers insulin spikes that lead to the build up of fatty plaques in the arteries — a risk factor for heart attacks and strokes. Artificial ...

Retatrutide mimics the effects of naturally occurring gut hormones to improve metabolic health. Stimulating insulin release ...

Insulin resistance in the brain is associated with obesity, type 2 diabetes, and cognitive dysfunction. Insulin normally regulates appetite and metabolism through brain signaling, but resistance ...

Get Instant Summarized Text (Gist) Aspartame, a common artificial sweetener, can increase insulin levels in mice, leading to atherosclerosis and inflammation in blood vessels. This process ...